Neurodevelopmental disorders affecting millions of children may share a common vulnerability: disrupted protein networks that control how brain cells communicate during critical growth periods. New therapeutic strategies are emerging that could restore normal neural function by targeting these fundamental molecular pathways. SYNGAP1-related disorder represents a distinct form of inherited brain dysfunction where mutations reduce production of SynGAP, a regulatory protein essential for proper synaptic development. This deficiency creates an imbalance between excitatory and inhibitory neural signals, manifesting as intellectual disability, seizures, and autism-spectrum behaviors. The protein normally acts as a molecular brake on Ras and Rap signaling cascades while orchestrating AMPA receptor positioning at synapses. When SynGAP levels drop by half due to genetic mutations, neurons lose their ability to fine-tune synaptic strength during development, leading to circuit-wide dysfunction. Recent advances in precision medicine offer promising interventions beyond traditional seizure medications. Gene supplementation therapies aim to restore normal SynGAP levels directly, while antisense oligonucleotides can modify gene splicing to increase functional protein production. Translation-activating RNAs represent another frontier, potentially boosting protein synthesis from remaining healthy gene copies. These approaches address the root molecular cause rather than merely managing symptoms. However, timing remains critical since SynGAP exerts its strongest influence during specific developmental windows. The cell-type specificity of SynGAP function also complicates therapeutic targeting, as different neuron populations may require distinct intervention strategies. While these precision approaches show laboratory promise, translating molecular insights into effective clinical treatments for children with neurodevelopmental disorders requires overcoming significant delivery and safety challenges.